Aviptadil as a Promising Intervention: A Case Study for Transfusion-Related Acute Lung Injury Treatment in a Cardiac Patient

Aviptadil is a synthetic form of vasoactive intestinal polypeptide (VIP) discovered in 1970 by Said and Mutt.1 VIP binds to the VPAC1 receptor of alveolar-type (AT) II cells, and has been shown to block replication of SARS-COV2, resulting in clinical and radiographic improvement. Sars-COV2 virus binds to AT II cells via the angiotensin-converting enzyme 2 receptor. Unlike other anticytokine drugs, aviptadil has a specific role in preserving lung surfactant production and protecting AT II cells. In the face of the COVID-19 pandemic, when all possible therapies were being explored, aviptadil was found to improve COVID-19 acute respiratory distress syndrome (ARDS), and received emergency approval from the Drug Controller General of India for the treatment of severe COVID-19 with ARDS.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Letter to the Editor Source Type: research